How many insider trades does FilingIQ track for NXTC?

FilingIQ tracks 46 Form 4 insider transactions for NXTC (NextCure, Inc.), covering filings from May 13, 2019 onwards. 14 of those are dated within the last 90 days.

Are NXTC insiders net buyers or net sellers?

Across the full Form 4 history for NXTC, 20 transactions (43%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NXTC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is NXTC in?

NextCure, Inc. (NXTC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $45.99M.

NXTC insider trading

Healthcare

NextCure, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

43% / 2%

Market cap

$45.99M

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Company website: www.nextcure.com

NXTC insider activity at a glance

FilingIQ tracks 46 insider transactions for NXTC in filings since May 13, 2019. The most recent transaction is dated Aug 10, 2026.

Across the full history, 20 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NXTC insider trades is 53.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live NXTC trades on FilingIQ Raw filings on SEC EDGAR

Latest NXTC Form 4 filings

Simcere Zaiming, Inc.

S Aug 12, 2026

ADAR1 Capital Management, LLC

P Aug 3, 2026

ADAR1 Capital Management, LLC

P Jul 29, 2026

Borgman Anne Elizabeth

Shaw Kevin G. Sr VP, General Counsel

A Feb 3, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 769

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

KYMR 127

Kymera Therapeutics, Inc.

ATTO 123

Attovia Therapeutics, Inc.

Frequently asked

How many insider trades does FilingIQ track for NXTC?: FilingIQ tracks 46 Form 4 insider transactions for NXTC (NextCure, Inc.), covering filings from May 13, 2019 onwards. 14 of those are dated within the last 90 days.
Are NXTC insiders net buyers or net sellers?: Across the full Form 4 history for NXTC, 20 transactions (43%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NXTC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is NXTC in?: NextCure, Inc. (NXTC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $45.99M.

Methodology & sources

Every NXTC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.